3960 Broadway
New York, NY 10032

Tel:    646-218-1850
Fax:   212-740-2570
Email:

About Forticell Bioscience, Inc.

 

About the Company

Mission Statement

Management Team

Board of Directors

Location & Directions

Careers

Investor Relations

Whats New

Contact

Press Release

For Immediate Release

WallSt.net Announces Upcoming Interview
with President of Forticell Bioscience

-------------------------------------------------------------------------------------------------------------------------------------

NEW YORK, Jan. 22 /PRNewswire - Dr. Costa Papastephanou, President and Chief Scientific Officer of Forticell Bioscience, Inc. (OTCBB: FORB) (forticellbioscience.com) will be featured in an exclusive interview with www.wallst.net scheduled for January 23 at 2:00 p.m. EST. The interview will be posted on www.wallst.net by 8 p.m. EST on January 23.

The interview will cover topics including Forticell’s market potential, growth initiatives, competitive edge, recent news, and milestones for which investors should watch.

To hear the interview in its entirety, visit http://www.wallst.net and click on "Interviews." The interview can be accessed by locating the company's ticker symbol under the appropriate exchange at the top of the "Interviews" section or by entering the company's ticker symbol in the Search Archive window.

About Forticell Bioscience, Inc.

Forticell Bioscience, Inc. is focused on advancing regenerative medicine and stem cell therapy through the development and commercialization of innovative products by combining advanced cell technology and advanced biomaterials. Forticell’s lead product is OrCel® (Bilayered Cellular Matrix). Forticell’s current focus is the application of OrCel® to heal chronic and acute wounds. OrCel® is composed of a collagen sponge seeded with allogeneic epidermal and dermal cells. These cells secrete growth factors and cytokines normally found in acute human wounds and are believed to have a beneficial role in promoting tissue regeneration.

Through Forticell Bioscience’s wholly owned Hapto subsidiary, the Company is expanding its human tissue engineering capabilities with the development of two fibrin derived advanced biomaterial technologies, Fibrin MicroBeads (FMB™) and Haptides™. These peptides have demonstrated the ability to significantly enhance cell attraction and attachment providing the potential to use Haptides™ in the development of product opportunities applicable to the cosmetic tissue augmentation and reconstruction, wound healing, orthopedics, and drug delivery markets.

Additional information about Forticell is available on the Internet at forticellbioscience.com

About WallSt.net:

www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The Website is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net, a financial social network for investors, Financial Filings Corp., a provider of compliance solutions to publicly traded companies, and WallStRadio, a business and finance podcast Website. Financial Filings Corp. is expecting to receive two hundred eighty dollars from Forticell Bioscience, Inc. for the dissemination of this press release. For a complete list of our advertisers and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp.

This news release may contain "forward-looking statements" for the purposes of the United States Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3B-6 under The Exchange Act. Without limitation, statements regarding expected FDA approvals, clinical trial results, product performance, expectations with respect to sales, gross margins, research and development expenditures, earnings per share, capital expenditures, collaborations, or other expansion opportunities would be “forward-looking statements.” These statements may be identified by words such as "expects", "anticipates", "intends", "estimates", "believes" or similar expressions in connection with any discussion of future financial and operating performance. The forward-looking statements contained herein involve risks and uncertainties that may cause results to differ materially from the Company's expectations including but not limited to, global economic trends, competitive pricing or product developments, government legislation and/or regulations, technology, manufacturing, legal and patent issues, suppliers, capital availability, personnel changes, cancellation or delays in renewal of contracts, and lack of suitable raw materials or packaging materials. Investors are cautioned to review risk factors in the Company's filings with the United States Securities and Exchange Commission.

FOR MORE INFORMATION, PLEASE CONTACT

At the Company: [email protected]

Ortec's Investor Relations Firm: Jordan Darrow at [email protected] or 631-367-1866


   Home   |   About Us   |   Product & Technology   |   Investor Relations   |   Contact   |   Site Map